DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H1 2018

  • ID: 4473116
  • Drug Pipelines
  • 25 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • MORE
DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H1 2018

Summary:

DNA Gyrase Subunit B (EC 5.99.1.3) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The latest report DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H1 2018, outlays comprehensive information on the DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

DNA Gyrase Subunit B (EC 5.99.1.3) - DNA gyrase is an essential bacterial enzyme that catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. DNA gyrase has two subunits. One of the subunit is B which introduces negative supercoils. Subunit B is selectively inactivated by antibiotics such as coumermycin A1 and novobiocin. Inhibition of either subunit blocks super twisting activity. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 4 and 1 respectively. Report covers products from therapy areas Infectious Disease which include indications Tuberculosis, Acinetobacter Infections, Bacterial Infections, Clostridium difficile Infections (Clostridium difficile Associated Disease), Escherichia coli Infections, Klebsiella pneumoniae Infections, Mycobacterium Infections and Neisseria gonorrhoeae Infections.

Furthermore, this report also reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for DNA Gyrase Subunit B (EC 5.99.1.3)
  • The report reviews DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics
Reasons to Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for DNA Gyrase Subunit B (EC 5.99.1.3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding DNA Gyrase Subunit B (EC 5.99.1.3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • MORE
Introduction

Report Coverage

DNA Gyrase Subunit B (EC 5.99.1.3) - Overview

DNA Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

DNA Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

DNA Gyrase Subunit B (EC 5.99.1.3) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Daiichi Sankyo Co Ltd

DNA Gyrase Subunit B (EC 5.99.1.3) - Drug Profiles

DS-2969 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GYR-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DNA GyrB for Tuberculosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPR-720 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-12008911 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXC-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNA Gyrase Subunit B (EC 5.99.1.3) - Dormant Products

DNA Gyrase Subunit B (EC 5.99.1.3) - Product Development Milestones

Featured News & Press Releases

May 30, 2017: Spero Therapeutics Presents New Data on SPR720 at ASM Microbe 2

May 04, 2017: Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by AstraZeneca Plc, H1 2018

Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Dormant Projects, H1 2018

List of Figures:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll